Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

被引：16
|
作者：
Sandoval-Sus, Jose D. [1 ]
Chavez, Julio C. [2 ]
Dalia, Samir [3 ]
Bello, Celeste M. [4 ]
Shah, Bijal D. [2 ]
Ho, Viet Q. [2 ]
Nodzon, Lisa [4 ]
Kharfan-Dabaja, Mohamed A. [5 ]
Sotomayor, Eduardo M. [6 ]
Sokol, Lubomir [7 ]
Pinilla-Ibarz, Javier [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA
[3] Mercy Clin Oncol & Hematol, Joplin, MO USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA
[6] George Washington Univ, Ctr Canc, Div Hematol Oncol, Washington, DC USA
[7] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2945.2945
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    PharmacoEconomics, 2024, 42 : 409 - 418
  • [22] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [23] Ibrutinib-Based Therapy in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia
    Kuvshinov, Alexey
    Voloshin, Sergei
    Martynkevich, Irina
    Martynenko, Ludmila
    Garifullin, Andrei
    Kleina, Elizaveta
    Shuvaev, Vasily
    BLOOD, 2016, 128 (22)
  • [24] Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies
    Karimi, Mohammad Amin
    Norooziseyedhosseini, Hanieh
    Khademi, Reza
    Ghajary, Alireza
    Kargar, Haniyeh
    Abdollahi, Seyyedeh Sana
    Belbasi, Mohaddeseh
    Naziri, Mahdyieh
    Deravi, Niloofar
    Hajihosseini, Sajjad
    Mofidi, Saharnaz
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [25] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
  • [26] Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib
    Jones, Jeffrey
    Choi, Michael Y.
    Mato, Anthony R.
    Furman, Richard R.
    Davids, Matthew S.
    Heffner, Leonard T.
    Cheson, Bruce D.
    Lamanna, Nicole
    Barr, Paul M.
    Eradat, Herbert
    Halwani, Ahmad
    Chyla, Brenda
    Zhu, Ming
    Verdugo, Maria
    Humerickhouse, Rod A.
    Potluri, Jalaja
    Wierda, William G.
    Coutre, Steven E.
    BLOOD, 2016, 128 (22)
  • [27] Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials
    Vorobyev, Vladimir I.
    Zherebtsova, Vera A.
    Dubrovin, Egor I.
    Bychenkova, Liudmila A.
    Butaev, Lev S.
    Muha, Larisa A.
    Kochkareva, Yulia B.
    Ivanova, Valentina L.
    Nikitin, Eugene A.
    Tumyan, Gayane
    Doronin, Vadim A.
    Krijanovski, Oleg I.
    Ptushkin, Vadim
    BLOOD, 2019, 134
  • [28] Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG)
    Iskierka-Jazdzewska, Elzbieta
    Pula, Bartosz
    Szeremet, Agnieszka
    Hus, Marek
    Golos, Aleksandra
    Holojda, Jadwiga
    Piszczek, Weronika
    Steckiewicz, Pawel
    Wojciechowska, Malgorzata
    Zaucha, Jan Maciej
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (08): : 1051 - 1057
  • [29] Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
    Cubillos-Zapata, Carolina
    Avendano-Ortiz, Jose
    Cordoba, Raul
    Hernandez-Jimenez, Enrique
    Toledano, Victor
    Perez de Diego, Rebeca
    Lopez-Collazo, Eduardo
    ONCOIMMUNOLOGY, 2016, 5 (12):
  • [30] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10911 - 10912
12345